{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:38:24Z","timestamp":1787780304052,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejca.2023.113290","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T16:18:10Z","timestamp":1691770690000},"page":"113290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study"],"prefix":"10.1016","volume":"193","author":[{"given":"Axel S.","family":"Merseburger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":false,"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabha","family":"Bhaumik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Lefresne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence I.","family":"Karsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea J.","family":"Pereira de Santana Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4026-082X","authenticated-orcid":false,"given":"\u00c1lvaro Ju\u00e1rez","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Given","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine D.","family":"Brookman-May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneel D.","family":"Mundle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon A.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3665-9523","authenticated-orcid":false,"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Bjartell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejca.2023.113290_bib1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.ejca.2023.113290_bib2","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ejca.2023.113290_bib3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2021.05.016","article-title":"Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy","volume":"80","author":"Sweeney","year":"2021","journal-title":"Eur Urol"},{"issue":"10336","key":"10.1016\/j.ejca.2023.113290_bib4","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d72 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2023.113290_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2022.04.002","article-title":"Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021","volume":"82","author":"Gillessen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2023.113290_bib6","doi-asserted-by":"crossref","unstructured":"Bossi A, Foulon S, Maldonado X, Sargos P, McDermott RS, Flechon A, et al. Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a phase 3 randomized trial with a 2\u00d72 design. Presented at: 2023 ASCO Annual Meeting, Chicago, IL, USA; 2023.","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5000"},{"issue":"32","key":"10.1016\/j.ejca.2023.113290_bib7","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.113290_bib8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.eururo.2023.04.002","article-title":"The efficacy of enzalutamide plus androgen deprivation therapy in oligometastatic hormone-sensitive prostate cancer: a post hoc analysis of ARCHES","volume":"84","author":"Armstrong","year":"2023","journal-title":"Eur Urol"},{"issue":"Suppl.6","key":"10.1016\/j.ejca.2023.113290_bib9","first-page":"115","volume":"40","author":"Armstrong","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl.15","key":"10.1016\/j.ejca.2023.113290_bib10","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1200\/JCO.2021.39.15_suppl.5071","article-title":"The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: a post hoc analysis of ARCHES","volume":"39","author":"Armstrong","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl.6","key":"10.1016\/j.ejca.2023.113290_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2021.39.6_suppl.102","article-title":"Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): post hoc analysis of the phase III ARCHES trial","volume":"39","author":"Azad","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2023.113290_bib12","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.113290_bib13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41391-021-00436-y","article-title":"Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk","volume":"25","author":"Azad","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.ejca.2023.113290_bib14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies","volume":"73","author":"Gravis","year":"2018","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ejca.2023.113290_bib15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.ejca.2023.113290_bib16","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase, respectively III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl.16","key":"10.1016\/j.ejca.2023.113290_bib17","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1200\/JCO.2022.40.16_suppl.5081","article-title":"Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): an analysis from the ECOG-ACRIN 3805 (CHAARTED) trial","volume":"40","author":"Tripathi","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl.16","key":"10.1016\/j.ejca.2023.113290_bib18","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1200\/JCO.2022.40.16_suppl.5070","article-title":"Defining more precisely the effects of docetaxel plus ADT for men with mHSPC: Meta-analysis of individual participant data from randomized trials","volume":"40","author":"Vale","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.113290_bib19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113290_bib20","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.113290_bib21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113290_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ejca.2023.113290_bib23","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl.3","key":"10.1016\/j.ejca.2023.113290_bib24","first-page":"e414","article-title":"Relationships of sites and burden of metastases with long-term outcomes and molecular subtypes in TITAN. Abstr MP24-08","volume":"206","author":"Bjartell","year":"2021","journal-title":"J Urol"},{"issue":"Suppl.2","key":"10.1016\/j.ejca.2023.113290_bib25","article-title":"Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis","volume":"19","author":"Bjartell","year":"2020","journal-title":"Eur Urol Open Sci"},{"issue":"Suppl.1","key":"10.1016\/j.ejca.2023.113290_bib26","doi-asserted-by":"crossref","first-page":"S1180","DOI":"10.1016\/S0302-2838(21)01220-3","article-title":"Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC): outcomes in high-volume (HV) and low-volume (LV) disease from the titan final analysis (FA)","volume":"79","author":"Chowdhury","year":"2021","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.ejca.2023.113290_bib27","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl.15","key":"10.1016\/j.ejca.2023.113290_bib28","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1200\/JCO.2020.38.15_suppl.5541","article-title":"Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: results from the TITAN and SPARTAN studies","volume":"38","author":"Chi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4S","key":"10.1016\/j.ejca.2023.113290_bib29","article-title":"Apalutamide for metastatic castration-sensitive prostate cancer in TITAN: prognostic importance of prostate-specific antigen responses","volume":"203","author":"Chowdhury","year":"2020","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113290_bib30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113290_bib31","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/JU.0000000000001568","article-title":"Efficacy of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread: ARCHES post hoc analyses","volume":"205","author":"Armstrong","year":"2021","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ejca.2023.113290_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113290_bib33","unstructured":"National Comprehensive Cancer Network. Prostate cancer. Version 1. 2023-September 16; 2022. Available from: \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf\u3009. [Accessed 15th November 2022]."},{"issue":"12","key":"10.1016\/j.ejca.2023.113290_bib34","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl.6","key":"10.1016\/j.ejca.2023.113290_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2022.40.6_suppl.089","article-title":"The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN","volume":"40","author":"Chi","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:50Z","timestamp":1760733710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923003921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":35,"alternative-id":["S0959804923003921"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113290","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113290"}}